Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Short Interest Update

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) was the target of a large decline in short interest in August. As of August 15th, there was short interest totalling 101,700 shares, a decline of 5.7% from the July 31st total of 107,900 shares. Based on an average daily trading volume, of 2,838,500 shares, the short-interest ratio is presently 0.0 days.

Bayer Aktiengesellschaft Stock Up 0.7 %

Shares of OTCMKTS:BAYRY opened at $7.72 on Monday. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.27 and a quick ratio of 0.86. The stock’s 50-day moving average price is $7.32 and its two-hundred day moving average price is $7.42. Bayer Aktiengesellschaft has a 12-month low of $6.82 and a 12-month high of $13.89.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last released its earnings results on Tuesday, August 6th. The company reported $0.25 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.25. The firm had revenue of $12 billion during the quarter. Bayer Aktiengesellschaft had a negative net margin of 2.74% and a positive return on equity of 16.96%. As a group, equities analysts expect that Bayer Aktiengesellschaft will post 1.37 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, The Goldman Sachs Group began coverage on shares of Bayer Aktiengesellschaft in a report on Thursday, May 30th. They set a “neutral” rating for the company. One analyst has rated the stock with a sell rating and eight have issued a hold rating to the stock. According to data from MarketBeat, Bayer Aktiengesellschaft has a consensus rating of “Hold”.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.